Adalimumab Biosimilar Drug Aliquot | Anti-TNF-α | Therapeutic Antibody

Aliquoted from the biosimilar drug | Now available for research use

Aliquots of the biosimilar Adalimumab (Hyrimoz®) are now available as research consumables.

Adalimumab biosimilar drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available. The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Adalimumab Biosimilar Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Hyrimoz® / Adalimimab Biosimilar Drug

Drug nameHyrimoz®
INNAdalimimab biosimilar
API typeAdalimumab is a biosimilar medicinal product. Is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary cells.
Pharmacotherapeutic groupImmunosuppressants, Tumour Necrosis Factor alpha (TNFα) inhibitors
ATC codeL04AB04
Target of antibodyTNFα
General functionAdalimumab is indicated for the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. Also indicate for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)After treatment with adalimumab, a rapid decrease in levels of acute phase reactants of inflammation (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage destruction were also decreased after adalimumab administration.
Original license holder
Marketing authorisation numbersEU/1/18/1286/001-007
Marketing authorisation holderSandoz GmbH
Biochemiestr. 10
6250 Kundl
Austria
Name of the manufacturer of the biological active substanceCatalent Biologics
1300 S. Patterson Drive
Bloomington
Indiana
47403
UNITED STATES

Sandoz GmbH
Biochemiestr. 10
6336 Langkampfen
AUSTRIA
Name and address of the manufacturer(s) responsible for batch releaseSandoz GmbH
Biochemiestr. 10
6336 Langkampfen
AUSTRIA
Max shelf life30 months
Storage conditions2°C – 8°C
List of excipientsAdipic acid
Citric acid monohydrate
Sodium chloride
Mannitol (E 421)
Polysorbate 80 (E 433)
Hydrochloric acid (for pH adjustment) (E 507)
Sodium hydroxide (for pH adjustment) (E 524)
Water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.